English
Slovak
Czech
Hungarian
Italian
Polish
Slovenian
Regeneron comes with an offer and a vision
Regeneron Pharmaceuticals, a renowned biopharmaceutical company, comes into play, which has decided to acquire almost all 23andMe's assets, as part of an auction taking place during the aforementioned bankruptcy process. Price? 256 million USD, which is a fraction of the former award, but at the same time an opportunity that many did not expect. As Regeneron President George Yancopoulos himself said, the goal is not only to acquire technology, but also to fulfill the original vision of 23andMe, this time with an emphasis on research and support for its own initiatives in the field of personalized health and prevention.
What Regeneron gets
The acquisition will include several key divisions, such as the well-known Personal Genome Service, the Total Health platform and, last but not least, research services that have often been used for drug development. Conversely, what Regeneron won't get is a subsidiary of Lemonaid Health, which 23andMe once bought for about $400 million. According to the announcement, it will be definitively abolished. However, the positive news is that Regeneron plans to offer jobs to all employees from the acquired divisions, which alleviates concerns about the fate of the talents who participated in building the brand, and who can still help Regeneron significantly in the future.
Strict conditions and privacy protection
Legally, the transaction is still awaiting approval by the Missouri Bankruptcy Court, with final closing expected in the third quarter of 2025. Given past issues related to the sensitivity of genetics and health data, the agreement is also conditional on the appointment of an independent privacy ombudsman to submit an evaluation report by June 10.
A new chance
From an investment perspective, this is an interesting example of how the technological and biotechnological spheres are beginning to intertwine again. For Regeneron, this represents a strategic move that can strengthen their ability to analyze and then personalize the treatment, which could potentially be reflected in the development of the share price [1], which, by the way, is in a correction of about 50%,* which is undoubtedly a more advantageous position to buy a fundamentally strong company, compared to entering the market at the peak of the stock price performance. On the contrary, for 23andMe, this is the last chance to leave at least part of the original mission.
Source: Trading Economics*
Conclusion
In conclusion, the current situation in which 23andMe finds itself serves as a reminder that even companies with the strongest vision can fail, especially if they do not have a clearly sustainable business model. The positive news is that a stable player from the world of biotechnology is entering bankruptcy, in combination with which the direction of the resulting company can be very promising from an investment point of view.
* Historical figures are not a guarantee of future returns.
[1] Forward-looking statements represent assumptions and current expectations that may not be accurate or are based on the current economic environment, which is subject to change. These statements do not guarantee future performance. Forward-looking statements involve risk and uncertainty by their nature because they relate to future events and circumstances that cannot be foreseen, and actual developments and results may differ materially from those expressed or implied in any forward-looking statements.
Warning! This marketing material is not and should not be construed as investment advice. Data relating to the past are not a guarantee of future returns. Investing in foreign currency can affect returns due to fluctuations. All securities trades can lead to both profits and losses. Forward-looking statements represent assumptions and current expectations that may not be accurate or are based on the current economic environment, which is subject to change. These statements do not guarantee future performance. InvestingFox is a trademark of CAPITAL MARKETS, o.c.p., a.s., regulated by the National Bank of Slovakia.
Resources:
